Company profile: Arranta Bio
1.1 - Company Overview
Company description
- Provider of contract development and manufacturing services, including GMP RNA solutions (plasmid, RNA, lipid nanoparticle production), biologics development and cGMP manufacturing, viral vector and live virus manufacturing, GMP cell and virus banking, and microbiome services developing and manufacturing live biotherapeutic products.
Products and services
- Microbiome Services: Engineers fermentation-based LBPs, leveraging bacterial fermentation, isolation, drying, and encapsulation to produce live biotherapeutics for inflammatory bowel disease and Clostridioides difficile infection
- RNA Technology: Delivers GMP-compliant RNA systems, producing plasmid, RNA, and lipid nanoparticle assemblies to support start-to-finish development and manufacturing for RNA-based projects
- Biologics Manufacturing Services: Builds cGMP manufacturing units prioritizing process consistency to fabricate animal cell‑derived viral and microbial products with reliable, repeatable performance
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arranta Bio
Sirion Biotech
HQ: Germany
Website
- Description: Provider of AAV, lentiviral, and adenoviral vectors for gene and cell therapy and vaccine development, including in vivo gene therapy for rare genetic diseases and ex vivo CAR-T applications; offers vector optimization (capsid/backbone, expression cassette), LentiBOOST transduction enhancer, custom viral vector engineering and manufacturing for research/preclinical, and GMP alliances via a global CDMO network.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirion Biotech company profile →
KaryoLogic
HQ: United States
Website
- Description: Provider of chromosome research services specializing in chromosomal aberration detection and chromosome analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KaryoLogic company profile →
FairJourney Biologics
HQ: Portugal
Website
- Description: Provider of end-to-end antibody discovery and development solutions, leveraging top-tier technologies and seasoned researchers to deliver high-quality, reliable antibodies tailored to partner needs. Services include customized cell line engineering for research and support from discovery to clinical trials; organizer of The Antibody Series on innovations in antibody discovery and development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FairJourney Biologics company profile →
Elligo Health Research
HQ: United States
Website
- Description: Provider of clinical research solutions that bring research to physician practices to accelerate the development of medical devices and therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elligo Health Research company profile →
ProSciento
HQ: United States
Website
- Description: Provider of clinical research and development services, leveraging broad scientific expertise, direct patient access, advanced methodologies, and integrated operations to advance science and achieve quality results through client and partner connections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProSciento company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arranta Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arranta Bio
2.2 - Growth funds investing in similar companies to Arranta Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arranta Bio
4.2 - Public trading comparable groups for Arranta Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →